At the Intersection of Science and Law

DLA Piper
  • 5.0 (2)
  • LIFE SCIENCES

In DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences team explore the connection between science and the law in areas that include AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.

  1. 11/15/2024

    Revolutionizing Clinical Trials: A discussion on diversity and patient-centric approaches

    In this episode, Quest Diagnostics’ Adam Donat is joined by DLA Piper’s Kirsten Axelsen, Rachel Portman, and Jae Kim to discuss the increasing complexity and cost of clinical trials, new FDA guidance, innovative trial designs and tools, and what’s expected in the new year. See omnystudio.com/listener for privacy information.

    30 min

  2. 05/19/2023

    Life sciences companies and the risks posed by the mifepristone litigation

    In this episode, a cross-disciplinary team of FDA regulatory lawyers and life sciences litigators discuss the implications of the mifepristone litigation for life sciences companies as it pertains to citizen petitions, FDA approvals, and strategies manufacturers might consider going forward. See omnystudio.com/listener for privacy information.

    33 min

  3. 04/12/2023

    Trade secrets protection in the life sciences sector

    DLA Piper’s Roberto Valenti and Ray Miller discuss trade secrets protection in the US and Europe and the peculiarities within the life sciences sector. Our speakers provide pragmatic approaches and suggestions on how to manage trade secrets for both pharmaceutical companies and medical device manufacturers. See omnystudio.com/listener for privacy information.

    21 min

  4. 02/06/2023

    Cross-border considerations for privacy in clinical trials

    Published in Chambers Expert Focus. With the recent publication of our Cross-border Guide to Clinical Trials and Privacy, James Clark, Paula Gonzalez de Castejón and David Kopans discuss ongoing and developing EU and US perspectives on privacy considerations with respect to cross-border clinical trials. See omnystudio.com/listener for privacy information.

    18 min

  5. 11/03/2022

    Global Life Sciences Supply Chain Insights

    Published in Chambers Expert Focus. Lauren Murdza and Richard Taylor share their insights on supply chain issues in the life sciences sector in the latest episode of At the Intersection of Science and Law. See omnystudio.com/listener for privacy information.

    28 min

  6. 09/06/2022

    AI risk assessments: Future-proofing your innovation when rules can change mid-game

    Published in Chambers Expert Focus. DLA Piper partner Danny Tobey is joined by Aviva Wein, Assistant General Counsel at Johnson & Johnson, to discuss how medical device and pharmaceutical companies are future-proofing their innovations in artificial intelligence as new regulations and risks arise. See omnystudio.com/listener for privacy information.

    25 min

  7. 06/01/2022

    The rise of global telehealth

    DLA Piper partners Kristi Kung and Greg Bodulovic discuss the rise of telehealth amid the COVID-19 pandemic, as well as advancements in technology aiming to address disparate access to healthcare globally. See omnystudio.com/listener for privacy information.

    26 min

  8. 04/18/2022

    Advising the advisor: Tips for navigating the life sciences and regulatory environment

    DLA Piper managing partner Emilio Ragosa is joined by Kevin Sheridan, Joint Global Head of Healthcare Investment Banking at Jefferies LLC, to discuss the importance of advisors having an understanding of the life sciences industry in order to provide value-added advice on transactions, including public offerings and M&A. See omnystudio.com/listener for privacy information.

    31 min
See All (14)

Ratings & Reviews

5
out of 5
2 Ratings

About

In DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences team explore the connection between science and the law in areas that include AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.

Information